Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VBIO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsValion Bio reports Q1 2026 financial results in routine earnings disclosure
Filed May 14, 2026 · Period ending May 14, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release announcing financial results for quarter ended March 31, 2026. Specific figures are in the attached exhibit, not disclosed in the 8-K body.
Item 2.02 verify on EDGAR → -
low
Filing references Exhibit 99.1 press release dated May 14, 2026, but the 8-K text appears incomplete with truncated Item 2.02 disclosure.
8-K: Exhibits verify on EDGAR →
Summary
Valion Bio filed a routine 8-K to announce its first quarter 2026 financial results. The company issued a press release on May 14, 2026, covering the quarter ended March 31, 2026, which is furnished as Exhibit 99.1. This is a standard quarterly earnings disclosure under Item 2.02.
Retail investors should note that the actual financial figures—revenue, earnings, cash position, and guidance—are contained in the press release exhibit, not in the 8-K body text itself. The filing text appears truncated or incomplete, which is unusual but may be a formatting issue rather than a substantive concern.
Watch for the full press release details in Exhibit 99.1 to assess the company's operational performance, cash burn rate, and any forward guidance provided. Compare results to prior quarters and analyst expectations to gauge business momentum.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Item 2.02 Results of Operations and Financial Condition. The information provided below in “
The filing begins to disclose Item 2.02 regarding results of operations and financial condition but the text is incomplete. Item 2.02 typically contains earnings announcements, press releases, or financial updates. Without the complete text, the specific financial results or operational updates cannot be determined.
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 14, 2026, the Company issued a press release regarding the Company’s financial results for the first quarter, ending March 31, 2026.
The company announced its financial results for the quarter ended March 31, 2026. The actual results are contained in the press release furnished as Exhibit 99.1, which is not included in this 8-K body text. This is a routine quarterly earnings disclosure.
Event · Item 9.01 — Financial Statements and Exhibits
Valion Bio filed an 8-K attaching a press release dated May 14, 2026; no material event details disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press Release, dated May 14, 2026.
The 8-K references an attached press release dated May 14, 2026, but does not disclose the content or subject matter of the release within the filing body itself. The actual material event, if any, would be contained in Exhibit 99.1.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify